Back to Authors

Brahmbhatt, Bhaumik

https://orcid.org/0000-0002-7013-2573

Mayo Clinic

Mayo Clinic in Florida

Citations 41

Cold snare endoscopic resection for large colon polyps: a randomised trial
Pohl, Heiko , Rex, Douglas K. , Barber, Jeremy, Moyer, Matthew T. , Elmunzer, B. Joseph , Rastogi, Amit , Gordon, Stuart R. , Zolotarevsky, Eugene, Levenick, John M. , Aslanian, Harry R., Elatrache, Mazen, Renteln, Daniel von , Brahmbhatt, Bhaumik , Keswani, Rajesh N. , Kumta, Nikhil A. , Smith, Zachary L. , Ghanimeh, Mouhanna K. Abu, Simmer, Stephen, MacKenzie, Todd A. , Piraka, Cyrus , von Renteln, Daniel , Smith, Zachary L , Piraka, Cyrus , Wallace, Michael B. , Pleskow, Douglas K. , Sanaei, Omid

Gut | May 20, 2025 | Volume: 74 | Issue: 11 | Pages: 1804-1813

10.1136/gutjnl-2025-335075 Get It

Background Complications of endoscopic mucosal resection (EMR) of large colorectal polyps remain a concern. Objective We aimed to compare safety and efficacy of cold EMR (without electrocautery) to hot EMR (with electrocautery) of large colorectal polyps. Design In this multicentre randomised trial, patients with any large (≥20 mm) non-pedunculated colon polyp were assigned to cold or hot EMR (primary intervention), and to submucosal injection with a viscous or non-viscous solution (secondary intervention) following a 2×2 design. The primary outcome was the rate of severe adverse events (SAEs). The secondary outcome was polyp recurrence. In this study, we report results of the primary intervention. Results 660 patients were randomised and analysed. An SAE was observed in 2.1% of patients in the cold EMR group and in 4.3% in the hot EMR group (p=0.10) (per protocol analysis 1.4 vs 5.0%, p=0.017) with fewer perforations following cold EMR (0%) compared with hot EMR (1.6%, p=0.028). Postprocedure bleeding did not differ (1.5% vs 2.2%, p=0.57). The effect of cold resection was independent of the type of submucosal injection solution, polyp size or antithrombotic medications. Recurrence was detected in 27.6% and 13.6% in the cold and hot EMR groups, respectively (p<0.001). Recurrence was not significantly different for 20–29 mm polyps (18.6% vs 13.4%, p=0.24) and for sessile serrated polyps (14.1% vs 8.5%, p=0.33). Conclusion Universal application of cold EMR did not significantly lower SAEs (unless cold EMR could be completed) and doubled the recurrence rate compared with hot EMR. Trial registration details ClinicalTrials.gov, number: NCT03865537 .
Type of submucosal injection solution for endoscopic resection of large colon polyps – results of a randomized trial
Pohl, Heiko , Rex, Douglas K. , Barber, Judy, Moyer, Matthew T. , Elmunzer, J, Rastogi, A. , Gordon, S, Zolotarevsky, Eugene, Levenick, John M. , Aslanian, Harry R., Elatrache, Mazen, Renteln, Daniel von , Brahmbhatt, Bhaumik , Keswani, Rajesh N. , Kumta, Nikhil A. , Ghanimeh, Mouhanna K. Abu, Simmer, Stephen, MacKenzie, Todd A. , Piraka, Cyrus , Barber, J, Wallace, Michael B. , Pleskow, Douglas K. , Smith, Zachary L. , Sanaei, Omid , Yang, Zhaohai

Endoscopy | March 27, 2025 | Volume: 57 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1805256 Get It

S1939 The Evolving Landscape of Drug Induced Liver Injury (DILI): Tracking New Drug Culprits
Maddineni, Gautam , Choday, Silpa, Vikash, Fnu , Pulakurthi, Yashwitha Sai, Kumar, Vikash , Shah, Mihir P., Chakinala, Raja Chandra , Boppana, Vaishnavi, Brahmbhatt, Bhaumik , Pan, Chun‐Wei , Shah, Mihir Prakash

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S1387-S1388

10.14309/01.ajg.0001037124.81921.b2 Get It

Use of glucagon‐like peptide‐1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease
Desai, Aakash , Patel, Harsh , Brahmbhatt, Bhaumik , Kochhar, Gursimran , Petrov, Jessica, Kochhar, Gursimran S , Desai, Aakash , Petrov, Jessica C , Hashash, Jana G. , Farraye, Francis A.

Alimentary Pharmacology & Therapeutics | June 28, 2024 | Volume: 60 | Issue: 5 | Pages: 620-632

10.1111/apt.18138 Get It

Summary Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) show anti‐inflammatory properties. Aim To evaluate their clinical impact on inflammatory bowel disease (IBD) outcomes. Methods Retrospective cohort study utilising the TriNetX database comparing IBD‐specific outcomes in patients with ulcerative colitis (UC) or Crohn's disease (CD) and type 2 diabetes mellitus (T2DM) on GLP‐1RA compared to oral hypoglycaemic agents. The primary outcome was hospitalisation requiring intravenous steroids and IBD‐related surgery within 3 years. We performed 1:1 propensity score matching (PSM) for demographics, co‐morbid conditions, BMI, laboratory values, HbA1c, and IBD medications including steroids. Results We identified 1130 patients in the UC GLP‐1RA cohort (mean age: 58.9 ± 11.6 years, 56.3% female, 70.2% White, 57.2% with obesity) and 1140 patients in the CD GLP‐1RA cohort (mean age: 56.7 ± 11.5, 61.9% female, 73.6% White, 56.2% with obesity). After PSM, there was no difference in the risk of intravenous steroid use (aHR: 1.21, 95% CI: 0.92–1.59) but a lower risk of colectomy (aHR: 0.37, 95% CI: 0.14–0.97) between the UC GLP‐1RA and control cohort. There was no difference in the risk of intravenous steroid use (aHR: 1.04, 95% CI: 0.80–1.34) but a lower risk of surgery (aHR: 0.55, 95% CI: 0.36–0.84) between the CD GLP‐1RA and CD control cohort. There was no difference in the risk of oral steroid use or advanced therapy initiation in the UC and CD GLP‐1RA than control cohorts. Conclusions We found an association between lower risk of IBD‐related surgery and GLP‐1RA use for T2DM in patients with UC or CD.
Lifestyle Medicine for the Prevention and Treatment of Pancreatitis and Pancreatic Cancer
Subramanian, Sruthi Kapliyil, Brahmbhatt, Bhaumik , Bailey, Jennifer M. , Mutha, Pritesh , Bailey-Lundberg, Jennifer M , Thosani, Nirav C

Diagnostics | March 14, 2024 | Volume: 14 | Issue: 6 | Pages: 614

10.3390/diagnostics14060614 Get It

The incidence of pancreatitis and pancreatic cancer is on the upswing in the USA. These conditions often lead to higher healthcare costs due to the complex nature of diagnosis and the need for specialized medical interventions, surgical procedures, and prolonged medical management. The economic ramification encompasses direct healthcare expenses and indirect costs related to productivity losses, disability, and potential long-term care requirements. Increasing evidence underscores the importance of a healthy lifestyle in preventing and managing these conditions. Lifestyle medicine employs evidence-based interventions to promote health through six key pillars: embracing a whole-food, plant-predominant dietary pattern; regular physical activity; ensuring restorative sleep; managing stress effectively; removing harmful substances; and fostering positive social connections. This review provides a comprehensive overview of lifestyle interventions for managing and preventing the development of pancreatitis and pancreatic cancer.
S498 Emerging Patterns of Esophageal Cancer: A Comprehensive Analysis of Incidence, Burden, and Mortality Trends in the United States, a Statewise Analysis over Three Decades (1990-2019)
Maddineni, Gautam , Choday, Silpa, Donepudi, Ashrita , Chadalawada, Sai Kiran, Tummala, Nayanika, Nelson, Alfred D. , Salami, Augustine, Brahmbhatt, Bhaumik

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S363-S364

10.14309/01.ajg.0000951632.90617.0e Get It

Disparities in colorectal cancer: Trends of reduced screening among minority populations.
Ouni, A. El , Garrett, Aneesah, Brahmbhatt, Bhaumik , Woodward, Timothy A., Ouni, Ahmed, Cardiel Nunez, Kristin E , Heckman, Michael G.

Journal of Clinical Oncology | January 24, 2023 | Volume: 41 | Issue: 4_suppl | Pages: 18-18

10.1200/jco.2023.41.4_suppl.18 Get It

18 Background: Studies have shown that African Americans (AA) are at increased risk for Colorectal Cancer (CRC) compared to other groups. Despite advancements in CRC screening modalities, few studies have investigated disparities in CRC screening among this vulnerable population. Methods: We performed a retrospective review of patients of age 45 or older who were seen in Family Medicine (FM), Internal Medicine (IM), or Gastroenterology (GI) between January 1, 2015 and December 31, 2021 at the Mayo Clinic. Information was collected regarding patient characteristics (age, sex, Charlson comorbidity score, race), and outcomes (whether a Cologuard test was ordered on the same day as the initial appointment, and whether the patient underwent a colonoscopy within 1 year after the initial appointment). Categorical variables were summarized with number and percentage of patients. Outcomes were compared between race groups (Caucasian, AA, Asian, Other) using unadjusted and multivariable logistic regression models. Multivariable models were adjusted for age, sex, and Charlson comorbidity score. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated. P-values <0.05 were considered as statistically significant, and all statistical tests were two-sided. Results: Overall, 558,078 were included for analysis and 14,607 (2.6%) were AA. Overall, AA patients for less likely to have Cologuard ordered compared to Caucasians (OR=0.62, p<0.001), notably driven by patient seen in the FM group (OR=0.54, p<0.001) and no statistically significant difference was observed in the IM and GI groups (p=0.055 and p=0.43, respectively). Notably, compared to Caucasian patients, Asian patients were overall more likely to have Cologuard ordered (OR=1.23, p=0.003). In multivariable analysis assessing the likelihood of having a colonoscopy performed within 1 year of the initial appointment, the likelihood of a colonoscopy within 1 year of initial clinic visit was significantly lower for AA compared to Caucasian patients (OR=0.50, p=0.028). This difference was strongest in FM patients (OR=0.26, p=0.022) and was not significant for IM (OR=0.67, p=0.37) or GI (OR=2.31, p=0.25). Conclusions: In this study, we found that AA ethnicity is associated with reduced likelihood of having Cologuard ordered compared to Caucasian patients. Furthermore, AA patients were less likely to have colonoscopy ordered within 1 year of initial visit clinic visit among the overall cohort, highlighting important disparities in CRC screening among this vulnerable patient population notably for those seen in the FM group. Future studies are needed to assess other barriers for CRC screening in this population.
Diet and carcinogenesis of gastric cancer
Maddineni, Gautam , Xie, Jesse J. , Brahmbhatt, Bhaumik , Mutha, Pritesh

Current Opinion in Gastroenterology | September 27, 2022 | Volume: 38 | Issue: 6 | Pages: 588-591

10.1097/mog.0000000000000875 Get It

Purpose of review Several recent studies have corroborated a strong association between diet and gastric cancer risk; investigators have also identified dietary factors that protect against gastric cancer. This review summarizes the literature on this topic and guides future research directions. Recent findings High-salt intake disrupts the gastric mucosal defense barrier, promoting Helicobacter pylori colonization and penetration of other carcinogenic compounds. Processed foods, processed meats, red meat, alcohol, foods with high dietary fat, and dietary cholesterol increase the risk of gastric carcinogenesis. On the other hand, increased consumption of fruits, vegetables, whole grains, nuts, and a low-salt diet may offer a protective effect. Summary Despite decreases in gastric cancer incidence because of increased identification and treatment of H. pylori, gastric cancer remains one of the most common cancers worldwide with a high mortality rate. This disturbing statistic highlights the importance of reducing and eliminating other risk factors for gastric cancer. There is a strong body of evidence that alcohol, processed foods, high salt intake, high fat intake, and foods with animal products (meats, eggs, and dairy) increase the risk of gastric cancer. A diet that is high in whole grains, fruits, vegetables, nuts and is low in salt may reduce the risk of gastric cancer.